Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.
Stocks · News reference
8-K filing — Inhibrx Biosciences, Inc. (INBX)
Filed: 2026-09-08 AccNo: 0002007919-26-000047 Size: 5 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Inhibrx Biosciences shares are trading lower. The company announced primary endpoint results from the Phase 2 HexAgon study of INBRX-106, an OX40 agonist, combined with pembrolizumab versus pembrolizumab alone in PD-L1 positive head and neck squamous cell carcinoma.
Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times